NCT00451152View on ClinicalTrials.gov

Safety and Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma

PHASE2CompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions
Open-angle Glaucoma
Interventions
DRUG

Anecortave Acetate Sterile Suspension, 30 mg/mL

Administered by anterior juxtascleral depot (AJD) in study eye, either 0.25 mL or 0.5 mL. One injection, 24 months.

OTHER

Anecortave Acetate Vehicle

Administered by anterior juxtascleral depot (AJD) in study eye, 0.5 mL. One injection, 24 months.

Trial Locations (1)

78257

Texas, San Antonio

Sponsors

Lead Sponsor

Alcon Research
All Listed Sponsors
lead

Alcon Research

INDUSTRY